Dupixent and a group of other specialty care products lifted sales of Sanofi SA in 2021 offsetting declines for legacy cardiovascular and diabetes products. At the same time, the company refreshed its portfolio with three acquisitions in the fourth quarter. Group turnover was €37.76 for the year, up by 4.8% from 2020. The increase was 7.1% when calculated using constant exchange rates. Sales of Dupixent, a treatment for asthma and other auto-immune diseases, amounted to €5.25 billion, up by 52.7% from the previous year.
